Monitor blood pressure periodically. Significant bladder outlet obstruction, patients taking antimuscarinic drugs for OAB: risk of urinary retention. Discontinue and treat if angioedema of the ...

Myrbetriq – sold as Betanis and Betmiga in ... Since that time, it has grown into one of Astellas’ top-selling drugs, bringing in worldwide revenues of 142 billion yen (around $918 million ...

For this report, we evaluated the following medications: darifenacin (Enablex); fesoterodine (Toviaz); mirabegron (Myrbetriq); oxybutynin (available as a pill [Ditropan XL and generic], a skin ...

A US district court has said that a key patent held by Astellas on its Myrbetriq drug for urinary incontinence is invalid, in a setback to its efforts to defend the blockbuster therapy from ...

In 2014 Myrbetriq entered the extremely crowded, commoditized market of products with the intent to become leader in the Overactive Bladder (OAB) treatment category. Using TV, social media, apps and ...